• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Artivion (AORT) Revenue Grew In Q3, Is The Selloff A Buying Opportunity?

    Simply Wall St·11/07/2026 06:29:40
    Listen to the news

    Artivion (AORT) released new third quarter results that pair higher revenue with a return to losses, and the mixed report appears to be weighing on a stock already under pressure this year.

    Artivion’s latest quarterly update landed alongside a sharp repricing, with the share price falling about 20% in the past day and roughly 10% over the past week as investors reacted to the earnings miss and swing back to losses.

    The setback extends a year of weak momentum, with the year to date share price return down about 55% and the 1 year total shareholder return also lower by about 55%. However, the 3 year total shareholder return remains positive at about 52%, which signals a very different experience for longer term holders.

    Scan beyond Artivion and see how it stacks up against 39 high quality undervalued stocks with stronger momentum or cleaner earnings trends in similar market conditions.

    Artivion now trades around $20.21 while analyst and intrinsic estimates cluster much higher, so the real puzzle is where fair value actually sits after this latest swing lower.

    Most Popular Narrative: 52% Undervalued

    Compared with Artivion's last close near $20.21, the most followed narrative pins fair value at $42. The current slide leaves a wide gap that hinges on whether the growth plan and product adoption thesis still hold after this quarter.

    Continued progress in obtaining regulatory approvals and launching products (e.g., BioGlue in China, Arcevo LSA pivotal trial in the U.S., and potential NEXUS approval via Endospan acquisition) is extending Artivion's geographic reach and product offerings, unlocking new growth regions and revenue streams while further diversifying earnings. Improvements in operational efficiency through leveraging existing sales infrastructure for new launches and maintaining strong pricing power, combined with significant deleveraging of the balance sheet, support expanding net margins, free cash flow, and financial flexibility for future growth investments.

    See why 4 investors see Artivion as 52% undervalued.

    Result: Fair Value of $42 (UNDERVALUED)

    Still, the bullish narrative around Artivion can unravel quickly if regulatory approvals slip, or if leverage and funding needs start to weigh more heavily on execution.

    Find out about the key risks to this Artivion narrative.

    Next Steps

    Mixed signals like this around Artivion can pull you in opposite directions, so move quickly, review the data for yourself, and weigh the 4 key rewards and 2 important warning signs

    Looking for more investment ideas beyond Artivion?

    If Artivion has you rethinking your next move, use this moment to widen your watchlist with fresh ideas built from clear, data driven filters.